Medical Technology Company Secures $35 Million in Equipment Financing From Wingspire Equipment Finance
Wingspire Equipment Finance has provided a $35 million equipment financing deal to a sponsor-backed medical technology company focused on sterile liquid medicines and vaccines. The financing will fund custom Blow-Fill-Seal (BFS) machines to enhance production capacity. The client company recently achieved significant innovations in prefilled injection devices, reducing costs by nearly 50%. The new BFS machines will improve unit production output, consolidate operations, reduce carbon footprint, and lower transportation costs. The capital lease structure was chosen over equity investment as a more cost-effective solution.
Wingspire Equipment Finance ha fornito un accordo di finanziamento per attrezzature di 35 milioni di dollari a una società di tecnologia medica sostenuta da sponsor, focalizzata su medicinali liquidi sterili e vaccini. Il finanziamento servirà a finanziare macchine Blow-Fill-Seal (BFS) personalizzate per aumentare la capacità produttiva. La società cliente ha recentemente raggiunto significativi traguardi nelle innovazioni dei dispositivi per iniezioni preriempite, riducendo i costi di quasi il 50%. Le nuove macchine BFS miglioreranno la produzione unitaria, consolideranno le operazioni, ridurranno l'impronta di carbonio e abbatteranno i costi di trasporto. È stata scelta una struttura di leasing del capitale piuttosto che un investimento in equity come soluzione più conveniente.
Wingspire Equipment Finance ha proporcionado un acuerdo de financiamiento de equipos de 35 millones de dólares a una empresa de tecnología médica respaldada por patrocinadores, centrada en medicamentos líquidos estériles y vacunas. El financiamiento se destinará a máquinas Blow-Fill-Seal (BFS) personalizadas para aumentar la capacidad de producción. La empresa cliente ha logrado recientemente innovaciones significativas en dispositivos de inyección precargados, reduciendo costos en casi un 50%. Las nuevas máquinas BFS mejorarán la producción unitaria, consolidarán operaciones, reducirán la huella de carbono y disminuirán los costos de transporte. Se eligió una estructura de arrendamiento de capital en lugar de una inversión patrimonial como una solución más rentable.
Wingspire Equipment Finance는 무균 액체 의약품 및 백신에 중점을 둔 스폰서 지원 의료 기술 회사에 3,500만 달러 장비 금융 거래를 제공했습니다. 이 자금은 생산 능력을 향상시키기 위해 맞춤형 Blow-Fill-Seal (BFS) 기계에 사용됩니다. 고객 회사는 최근 주사기 미리 채워진 장치에서 중요한 혁신을 달성하여 비용을 거의 50% 줄였습니다. 새로운 BFS 기계는 단위 생산량을 개선하고, 운영을 통합하며, 탄소 발자국을 줄이고, 운송 비용을 낮출 것입니다. 자본 리스 구조는 보다 비용 효율적인 솔루션으로 주식 투자보다 선택되었습니다.
Wingspire Equipment Finance a fourni un accord de financement d'équipement de 35 millions de dollars à une société de technologie médicale soutenue par des sponsors, axée sur les médicaments liquides stériles et les vaccins. Le financement permettra d'acquérir des machines Blow-Fill-Seal (BFS) sur mesure pour améliorer la capacité de production. La société cliente a récemment réalisé d'importantes innovations dans les dispositifs d'injection préremplis, réduisant les coûts de près de 50 %. Les nouvelles machines BFS amélioreront la production unitaire, consolideront les opérations, réduiront leur empreinte carbone et diminueront les coûts de transport. La structure de location-capital a été choisie plutôt qu'un investissement en capital-actions comme solution plus rentable.
Wingspire Equipment Finance hat einem von Sponsoren unterstützten Medizintechnikunternehmen, das sich auf steriles Flüssigkeitsmedikamenten und Impfstoffe konzentriert, ein 35 Millionen Dollar Ausstattungsfinanzierungsgeschäft angeboten. Die Finanzierung wird zur Anschaffung maßgeschneiderter Blow-Fill-Seal (BFS) Maschinen verwendet, um die Produktionskapazität zu erhöhen. Das Kundenunternehmen hat kürzlich bedeutende Innovationen bei vorgefüllten Injektionsgeräten erzielt, wodurch die Kosten um fast 50 % gesenkt wurden. Die neuen BFS-Maschinen werden die Produktionsausbeute pro Einheit verbessern, die Abläufe konsolidieren, den CO2-Fußabdruck reduzieren und die Transportkosten senken. Die Entscheidung fiel auf eine Kapitalleasingstruktur anstelle einer Eigenkapitalinvestition als kosteneffektivere Lösung.
- Secured $35 million in equipment financing
- Achieved 50% cost reduction in prefilled injection devices
- Equipment acquisition will improve production efficiency and reduce operational costs
- None.
Insights
The
The capital lease structure will fund specialized BFS machines that should drive significant operational improvements through:
- Increased production capacity
- Operational consolidation
- Reduced transportation costs
- Lower carbon footprint
The medical technology company specializes in helping pharmaceutical manufacturers design rapidly scalable, cost-efficient drug delivery systems. The company recently made monumental innovations in its prefilled injection devices, reducing costs by nearly
The finance structure will support the acquisition of specialized equipment integral to the company’s prefilled drug delivery systems. The new BFS machines are designed to improve unit production output, consolidate operations into fewer facilities, reduce the company's carbon footprint, and lower transportation costs.
"Timing was critical for the client," said Mark Ellis, Vice President of Originations at Wingspire Equipment Finance. "By understanding our client's specific capital structure needs, we delivered a tailored financing package that addressed their immediate challenges while providing the flexibility to support their future growth. Our solution met their current needs and set them up for continued production expansion into 2025."
For more information about Wingspire Equipment Finance and its comprehensive finance solutions, please visit ef.wingspirecapital.com.
About Wingspire Equipment Finance:
Wingspire Equipment Finance is a leading provider of equipment financing solutions, committed to empowering businesses with flexible and innovative financial solutions. With a focus on client success and industry expertise, Wingspire Equipment Finance is dedicated to helping companies thrive by providing tailored financing options for their equipment needs.
About Wingspire Capital:
Wingspire Capital provides senior secured credit facilities of up to
Wingspire Capital is a portfolio company of Blue Owl Capital Corporation (NYSE: OBDC). OBDC is externally managed by Blue Owl Credit Advisors LLC, an indirect affiliate of Blue Owl Capital, Inc. (NYSE: OWL). Blue Owl Capital, Inc. is a global alternative asset manager with over
View source version on businesswire.com: https://www.businesswire.com/news/home/20241107651124/en/
For media inquiries, please contact:
Media Relations
844.816.9420
pressinfo@wingspirecapital.com
Source: Wingspire Equipment Finance
FAQ
How much equipment financing did the medical technology company secure from Wingspire?
What will the $35 million equipment financing be used for?
What cost reduction did the medical technology company achieve in their prefilled injection devices?
